Status:

COMPLETED

Effect of SARSCoV2 (COVID-19) Vaccination in Type 1 Diabetes (CoVaxT1D)

Lead Sponsor:

Paolo Fiorina, MD

Collaborating Sponsors:

ASST Fatebenefratelli Sacco

Conditions:

Type 1 Diabetes

Eligibility:

All Genders

16+ years

Brief Summary

Given the high risk of severe SARS-CoV-2 infection, patients with T1D and T2D should represent a priority group to receive the SARS-CoV-2 vaccine. There are currently no studies on diabetic population...

Detailed Description

Since the beginning of the COVID-19 pandemic in March 2020, more than 160 million people have suffered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and more than 3 mill...

Eligibility Criteria

Inclusion

  • Inclusion Criteria for patients with type 1 diabetes:
  • age \>16
  • History of type 1 diabetes
  • previous blood test in search for SARSCoV2 antibodies
  • willingness to provide informed consent
  • Exclusion Criteria for patients with type 1 diabetes:
  • age \<16 years
  • Systemic infections
  • Diabetic ketoacidosis in the past 6 weeks
  • COVID-19 diagnosis in the previous 6 months
  • Inclusion Criteria for non-diabetic subjects:
  • age \>16
  • No previous history of diabetes
  • previous blood test in search for SARSCoV2 antibodies
  • willingness to provide informed consent
  • Exclusion Criteria for non-diabetic subjects:
  • age \<16 years
  • Systemic infections
  • COVID-19 diagnosis in the previous 6 months
  • Inclusion Criteria for patients with type 2 diabetes:
  • age \>16
  • History of type 2 diabetes but no evidence of autoantibodies
  • previous blood test in search for SARSCoV2 antibodies
  • willingness to provide informed consent
  • Exclusion Criteria for patients with type 2 diabetes:
  • age \<16 years
  • Systemic infections
  • COVID-19 diagnosis in the previous 6 months

Exclusion

    Key Trial Info

    Start Date :

    March 31 2021

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    June 30 2022

    Estimated Enrollment :

    600 Patients enrolled

    Trial Details

    Trial ID

    NCT04905823

    Start Date

    March 31 2021

    End Date

    June 30 2022

    Last Update

    May 10 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    ASST FBF-Sacco P.O. Sacco

    Milan, MI, Italy, 20157